Presentation by Dr Fraser Gibb, Edinburgh​​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Jackie Elliott, Sheffield​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Nicola Taylor, Dietitian, Derby​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Emma Wilmot, Derby​, DTN-UK Chair

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Geraldine Gallen, DSN, London

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Peter Hammond, Harrogate​​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Mike Kendall, DTN-UK representative​

Part of the DTN-UK Flash Glucose Monitoring Education Programme

Presentation by Dr Emma Wilmot, Derby​, DTN-UK Chair

Part of the DTN-UK Flash Glucose Monitoring Education Programme

In this double-blind, randomized trial, 'abstract of published paper' assigned patients with type 2 diabetes and

albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor,

at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular

filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area

This next deadline of 21st May for data submission to the ABCD nationwide FreeStyle Libre audit has been set for two reasons.  An updated analysis will be undertaken to form the data that will be presented at the  American Diabetes Association annual professional conference between June 7-11, 2019.  This analysis will then be used to write the first paper to be published from the audit.  Data collection will continue beyond this date though 21^st May is an important milestone.